scholarly journals The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective

2017 ◽  
Vol 19 (5) ◽  
pp. 661-669 ◽  
Author(s):  
Martin R. Cowie ◽  
Marcus Simon ◽  
Liviu Klein ◽  
Praveen Thokala
Keyword(s):  
Heart Failure ◽  
Cost Effectiveness ◽  
Pulmonary Artery ◽  
Real Time ◽  
Pulmonary Artery Pressure ◽  
European Perspective ◽  
Pressure Monitoring ◽  
Heart Failure Patients ◽  
Artery Pressure ◽  
The Cost

scholarly journals Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure

2016 ◽  
Vol 4 (5) ◽  
pp. 368-375 ◽  
Author(s):  
Alexander T. Sandhu ◽  
Jeremy D. Goldhaber-Fiebert ◽  
Douglas K. Owens ◽  
Mintu P. Turakhia ◽  
Daniel W. Kaiser ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cost Effectiveness ◽  
Chronic Heart Failure ◽  
Pulmonary Artery ◽  
Pulmonary Artery Pressure ◽  
Pressure Monitoring ◽  
Artery Pressure

scholarly journals Improving the monitoring of chronic heart failure in Argentina: is the implantable pulmonary artery pressure with CardioMEMS Heart Failure System cost-effective?

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Andrea Alcaraz ◽  
Carlos Rojas-Roque ◽  
Daniela Prina ◽  
Juan Martín González ◽  
Andrés Pichon-Riviere ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cost Effectiveness ◽  
Pulmonary Artery ◽  
Medical Care ◽  
Pulmonary Artery Pressure ◽  
Cost Effective ◽  
Class Iii ◽  
Lifetime Horizon ◽  
Artery Pressure ◽  
The Cost

Abstract Background The CardioMEMS® sensor is a wireless pulmonary artery pressure device used for monitoring symptomatic heart failure (HF). The use of CardioMEMS was associated with a reduction of hospitalizations of HF patients, but the acquisition cost could be high in low-and-middle income countries. Evidence of cost-effectiveness is needed to help decision-makers to allocate resources according to “value for money”. This study is aimed at estimating the cost-effectiveness of CardioMEMS used in HF patients from the third-party payer perspective -Social Security (SS) and Private Sector (PS)- in Argentina. Methods A Markov model was developed to estimate the cost-effectiveness of CardioMEMS versus usual medical care over a lifetime horizon. The model was applied to a hypothetical population of patients with HF functional class III with at least one hospitalization in the previous 12 months. The main outcome was the incremental cost-effectiveness ratio (ICER). To populate the model we retrieved clinical, epidemiological and utility parameters from the literature, whilst direct medical costs were estimated through a micro-costing approach (exchange rate USD 1 = ARS 76.95). Uncertainties in all parameters were assessed by deterministic, probabilistic and scenario sensitivity analysis. Results Compared with the usual medical care, CardioMEMS increased quality-adjusted life years (QALY) by 0.37 and increased costs per patient by ARS 1,081,703 for SS and ARS 919,051 for PS. The resultant ICER was ARS 2,937,756 per QALY and ARS 2,496,015 per QALY for SS and PS, respectively. ICER was most sensitive to the hazard ratio of HF hospital admission and the acquisition price of CardioMEMS. The probability that CardioMEMS is cost-effective at one (ARS 700,473), three (ARS 2,101,419,) and five (ARS 3,502,363) Gross Domestic Product per capita is 0.6, 17.9 and 64.1% for SS and 5.4, 33.3 and 73.2% for PS. Conclusions CardioMEMS was more effective and more costly than usual care in class III HF patients. Since in Argentina there is no current explicit threshold, the final decision to determine its cost-effectiveness will depend on the willingness-to-pay for QALYs in each health subsector.

scholarly journals Wireless Pulmonary Artery Pressure Monitoring Improves Physical Activity of Heart Failure Patients

2017 ◽  
Vol 23 (8) ◽  
pp. S82-S83
Author(s):  
Ashley E. Burch ◽  
David M. Sager ◽  
Samuel F. Sears ◽  
Tracy Vaughan ◽  
Alison Cieszko ◽  
...  
Keyword(s):  
Physical Activity ◽  
Heart Failure ◽  
Pulmonary Artery ◽  
Pulmonary Artery Pressure ◽  
Pressure Monitoring ◽  
Heart Failure Patients ◽  
Artery Pressure

scholarly journals Improving the Monitoring of Chronic Heart Failure in Argentina: Is the Implantable Pulmonary Artery Pressure with CardioMEMS Heart Failure System Cost-effective?

2021 ◽  
Author(s):  
Andrea Alcaraz ◽  
Carlos Rojas-Roque ◽  
Daniela Prina ◽  
Juan Martín González ◽  
Andres Pichon-Riviere ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cost Effectiveness ◽  
Pulmonary Artery ◽  
Medical Care ◽  
Pulmonary Artery Pressure ◽  
Cost Effective ◽  
Class Iii ◽  
Lifetime Horizon ◽  
Artery Pressure ◽  
The Cost

Abstract Background. The CardioMEMS® sensor is a wireless pulmonary artery pressure device used for monitoring symptomatic heart failure (HF). The use of CardioMEMS was associated with a reduction of hospitalizations of HF patients, but the acquisition cost could be high in low-and-middle income countries. Evidence of cost-effectiveness is needed to help decision-makers to allocate resources according to “value for money”. This study aimed to estimate the cost-effectiveness of CardioMEMS use in HF patients from the third-party payer perspective -Social Security (SS) and Private Sector (PS)-in Argentina.Methods. A Markov model was developed to estimate the cost-effectiveness of CardioMEMS versus usual medical care, over a lifetime horizon. The model was applied to a hypothetical population of patients with HF functional class III with at least one hospitalization in the previous 12 months. The main outcome was the incremental cost-effectiveness ratio (ICER). To populate the model we retrieved clinical, epidemiological and utility parameters from the literature, whilst direct medical costs were estimated through micro-costing approach (exchange rate USD 1 = ARS 76.95). Uncertainty in all parameters were assessed by deterministic, probabilistic and scenario sensitivity analysis.Results. Compared with the usual medical care, CardioMEMS increased QALY by 0.37 and increased costs per patient by ARS 1,081,703 for SS and ARS 919,051 for PS. The resultant ICER was ARS 2,937,756 per QALY and ARS 2,496,015 per QALY for SS and PS respectively. ICER was most sensitive to the hazard ratio of HF hospital admission and the acquisition price of CardioMEMS. The probability that CardioMEMS is cost-effective at one (ARS 700,473), three (ARS 2,101,419,) and five (ARS 3,502,363) GDP per capita is 0.6%, 17.9% and 64.1% for SS and 5.4%, 33.3% and 73.2% for PS.Conclusions. CardioMEMS was more effective and more costly than usual care in class III HF patients. Since in Argentina there is no current explicit threshold, the final decision to determine its cost-effectiveness will depend on the willingness-to-pay for QALYs in each health subsector.

Safety and accuracy of a wireless pulmonary artery pressure monitoring system in patients with heart failure

2011 ◽  
Vol 161 (3) ◽  
pp. 558-566 ◽  
Author(s):  
William T. Abraham ◽  
Philip B. Adamson ◽  
Ayesha Hasan ◽  
Robert C. Bourge ◽  
Salpy V. Pamboukian ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Artery ◽  
Monitoring System ◽  
Pulmonary Artery Pressure ◽  
Pressure Monitoring ◽  
Artery Pressure ◽  
Patients With Heart Failure
Sign in / Sign up

Export Citation Format

Share Document